A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT04678648
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Malignant Solid Neoplasm
- RAS Mutation
- Lung Cancer
- Colon Cancer
- Glioblastoma
- Pancreatic Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- RasCal Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- June 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology · Los Angeles, CA
Colorado · 1
- Sarah Cannon, SCRI Oncology Partners - Health One · Denver, CO
Tennessee · 1
- Sarah Cannon, SCRI Oncology Partners · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.